

Novartis unveils unprecedented results for the treatment of advanced breast cancer in premenopausal patients

At the 2019 American Society of Clinical Oncology (ASCO) meeting, Novartis announced that its CDK4/6 inhibitor, ribociclib significantly extends life in premenopausal women with advanced breast cancer. Ribociclib is used in combination with endocrine therapy.